just my opinion, developing pipeline is risky, it’s all essentially the same stuff, if any one trial goes bad could devalue the whole lot, and CBD is too political still, policy changing to give FDA more control over it as a medical product, but to me pipeline is as advanced as BOT need it to be right now.
They said they want to grow it, so I think they’ll either licence or launch SB, use money to buy another thing, launch it, buy another thing. If that’s their thinking, I don’t see them selling for less than $2-3 per share.
Bot Chart, page-10572
-
- There are more pages in this discussion • 2,812 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.8¢ |
Change
-0.018(4.79%) |
Mkt cap ! $559.1M | |||
| Open | High | Low | Value | Volume |
| 36.0¢ | 36.5¢ | 34.8¢ | $1.500M | 4.234M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 274936 | 34.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 353890 | 7 |
View Market Depth
| Last trade - 10.55am 26/06/2024 (20 minute delay) ? |
| BOT (ASX) Chart |